Safety and Efficacy of Topical Simvastatin Plus Cholesterol Cream vs Topical Simvastatin Cream Alone for Porokeratosis Ptychotropica: A randomized, single-blind, split-body, placebo-controlled investigator-initiated trial

Supplementary Fig 1. The genotype and phenotype of the 18 enrolled patients. Supplementary Fig 2. The clinical responses of porokeratosis ptychotropica patients after topical simvastatin treatment. Supplementary Fig 3. The improvement ratio of porokeratosis ptychotropica patients from the 2% simvastatin and the 2% simvastatin/2% cholesterol group at preliminary assessment (week 8). Supplementary Fig 4. Analysis of the PPASI score decline from baseline to week 48 of porokeratosis ptychotropica patients between the 2% simvastatin and the 2% simvastatin/2% cholesterol group. Supplementary Fig 5. The responses of erythema, thickness, and scaling after topical simvastatin treatment. Supplementary Table I. The PPASI score about the degree of redness (erythema, E), thickness (induration, I), and scaling (desquamation, D) of the lesions. Supplementary Table II. The score of the affected area was assigned with the percentage of affected body surface area (BSA) on the buttocks.